share_log

HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $4 Price Target

Benzinga ·  Jun 21, 2023 11:46

HC Wainwright & Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $4 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment